<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142937">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923584</url>
  </required_header>
  <id_info>
    <org_study_id>EPIPD</org_study_id>
    <nct_id>NCT01923584</nct_id>
  </id_info>
  <brief_title>A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of EPI-743 in patients with Parkinson's
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>electroretinogram and color vision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurologic function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>UPDRS subscales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>UPDRS subscales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain metabolites</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Magnetic Resonance spectroscopy (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease biomarkers</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood biomarker levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>EPI-743 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI-743 at a dose of 400 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI-743 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI-743 at a dose of 200 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743 400mg</intervention_name>
    <arm_group_label>EPI-743 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743 200mg</intervention_name>
    <arm_group_label>EPI-743 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Parkinson's disease

          2. Age 40 - 75

          3. Ambulatory with or without assistance

          4. Hoehn and Yahr Scale score of 1 - 3

          5. Patient able to consent and comply with protocol requirements

          6. Abstention from use of Coenzyme Q10, vitamin E, Azilect and Idebenone two weeks prior
             to enrollment and during course of treatment with EPI-743

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil

          2. Allergy to vitamin E

          3. Clinical history of bleeding or abnormal baseline PT/PTT

          4. Diagnosis of any other neurologic disease

          5. Malignancy within past two years

          6. Pregnant or plans to become pregnant

          7. Concomitant ophthalmologic disease

          8. History of stroke

          9. History of brain surgery

         10. Inability to undergo MRI scan or MRS

         11. Hepatic insufficiency with LFTs greater than two times upper limit of normal

         12. Renal insufficiency requiring dialysis

         13. End stage cardiac failure

         14. Fat malabsorption syndromes precluding drug absorption

         15. Use of anticoagulant medications, azilect
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Ward</last_name>
    <phone>813-974-5909</phone>
    <email>cward2@health.usf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Sullivan, PhD</last_name>
    <phone>813-974-5909</phone>
    <email>kbarber@health.usf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Ward</last_name>
      <phone>813-974-5909</phone>
      <email>cward2@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>August 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
